Introduction: Allergic conjunctivitis (AC), dry eye syndrome (DES), and computer vision syndrome (CVS) are few of the eye diseases that commonly affect the working class. Allergic conjunctivitis is often associated with Kaphaja abhishyanda. Dry eye syndrome is caused due to chronic lack of sufficient lubrication and moisture on the surface of the eye. The CVS is a visual complaint that is clinically similar to DES. In Ayurveda, the symptoms of DES can be included under the spectrum of two different diseases, Krichronmeela and suskakshipaka. Tarpana, Aschyotana, Nasya, and oral use of Ayurvedic medicines are commonly advocated for eye diseases.
INTRODUCTION
Eye is the most important sense organ in our body, and any disease that affects the functioning of eye should be diagnosed and treated with great caution.
Allergic conjunctivitis, DES, and CVS are few of the eye diseases that commonly affect the working class. Ocular allergy represents one of the most common ocular conditions encountered in clinical practice. 1 The AC is an inclusive term that encompasses many allergic conditions, which cause the symptom of conjunctivitis.
Irrespective of the type of cause, symptomatology consists of itching, redness, increased lacrimation, and swelling of the conjunctiva. 1 Kaphaja abhishyanda, a variety of abhishyanda mentioned in Ayurveda classics, is etiologically and clinically similar to AC. Symptoms, such as itching and chemosis are the predominant symptoms of kaphaja abhishyanda and redness of eyes is produced by the involvement of rakta. The DES is a common disorder, characterized by instability of the tear film that can be due to insufficient amount of tear production or due to poor quality of tear film, which results in increased evaporation of the tears. 2 The main symptom of dry eyes is a dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain, redness of the eyes, and photophobia in some cases. 3 Around the world, it has been estimated that nearly 60 million people experience vision problems as a result of computer use, which has become a part and parcel of today's life. 4 Both visual and ophthalmic symptoms occur among computer users. These have collectively been called the CVS. However, the major contributor to CVS symptoms by far appears to be dry eye. 5 It is estimated that daily usage of the computer for more than 2 hours may result in a 90% chance to develop CVS. 6 The CVS is clinically similar to DES as they both share the symptoms of dryness of eye. Visual complaints include blurred vision, burning, stinging, and photophobia. 4 In Ayurveda, the symptoms of DES can be associated with two different diseases, Krichronmeela (mentioned by Vagbhata) and sushkakshipaka (mentioned by Susrutha). The initial stages may begin with symptoms of krichronmeela and later when there are structural changes, it can be compared with suskakshipaka. 7, 8 The current treatment of common eye diseases as per modern modality is limited. Frequent dosing of up to 4 times per day and topical antihistamines may be irritating to the eye, especially with prolonged use. 9 In order to limit the potential side effects and find out safe and effective drugs that give a long-lasting effect, exploration of Ayurvedic medicines is the need of the hour. There is vivid description of many Ayurvedic formulations and procedures in Ayurveda classics, which are beneficial in the treatment of common eye diseases.
Ayurvedic treatment, in addition to administration of Ayurvedic medicine orally, includes Tarpana, Aschyotana, and Nasya for eye diseases. Mahatriphaladya ghrita, Triphala kwath, and Anu taila are few among the multitudes of formulations that are presently in use and this set of studies was done to analyze the safety of Mahatriphaladya ghrita, Triphala kwath, and Anu taila in patients with AC, DES, and CVS.
Drug Profile
In Ayurveda texts, Mahatriphaladya ghrita is exclusively mentioned in the context of Netraroga (eye disorder). This formulation is mentioned in Bhaisajya Ratnavali and its important therapeutic uses are Naktandhya (night blindness), Timira (early stage of cataract), Kaca (cataract), Nilika (mole), Patala Arbuda (growth in layers of eye), Netrabhisyanda (conjunctivitis), Adhimantha (glaucoma) Pakshmakopa (trichiasis/entropion), Netraroga (eye disorder), Adrishti (loss of eyesight), Mandadristhi (diminished vision), Netrasrava (chronicdacrocystitis/epiphora), Netrakandu (itching in eyes), Duradrishti (hypermetropia/ hyperopia), and Samipadrishti (myopia).
Triphala kwath is also mentioned in Bhaisajya Ratnavali and its important therapeutic uses are for Netraroga (eye disorder) and for Dhavana (cleansing). Triphala has been used for internal and external purposes since time immemorial, and is mentioned as Chakshushya rasayana (medicine that adds vitality and promotes the health of eyes) by Ayurveda.
Anu taila is mentioned in Astangahrdaya, sutrasthan and its important therapeutic uses are urdhvajatrugata Roga (disorders of body parts above clavicle), Tvakrauksya (dryness of skin), Palita (graying of hair), Skandha suskata (emaciation of shoulder), Grivasuskata (wasting in cervical region), and Vakshasuskata (emaciation of chest muscles) ( Table 1) . 
MATERIALS AND METHODS
The formulations fulfilling the physicochemical standards and quality parameters, and prepared as per standard operating procedures, were used for all the studies. These three different clinical studies were approved by the Institutional Ethics Committee of all the participating centers and done in accordance with World Health Organization Good Clinical Practice Guidelines. The study medications included Mahatriphaladya ghrita (15 mL twice daily given with lukewarm water for a period of 12 weeks) in the AC and DES for 84 days. Mahatriphaladhya ghrita was also used in CVS in the dose of 5 mL twice daily for 42 days.
Triphala kwath was used for aschyotana in AC (10 drops twice a day for 12 weeks) and Mahatriphaladya ghrita topically for Tarpana in DES and CVS (20 mL once a day for 5 consecutive days in the morning and repeated at an interval of 4 weeks in DES, 3 days in the morning and repeated at 15 days in CVS). Anu tail nasya, 8 drops in each nostril was administered for 7 days in CVS. Followup was done finally after 2 weeks without medication and to record the onset of any adverse reaction during the intervention in all the three studies.
Open labeled multicenter clinical trials were done in selected peripheral institutes of CCRAS to evaluate the safety and efficacy of Mahatriphaladya ghrita, Triphala kwath, and Anu taila in common eye diseases. All the three studies were registered in the Clinical Trial Registry of India. The details are briefed in Table 2 . The data obtained from the completed clinical studies were analyzed prospectively to assess the safety profile of Mahatriphaladya ghrita through LFTs and KFTs.
Statistical Analysis
Laboratory parameters at the beginning and at the end of the trial period were compared using paired t-test. A p-value of <0.05 was considered significant. All statistical analysis was performed using Statistical Package for the Social Sciences version 15.0.
OBSERVATION Study I: Effect of Mahatriphaladya ghrita and Triphala kwath in AC
Oral administration of Mahatriphaladya ghrita and Triphala kwath Aschyotana for 84 days revealed significant (Tables 3 and 4 , Graphs 1 to 4). 
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Study II: Effect of Mahatriphaladya ghrita in DES
Oral administration and topical treatment (Tarpana) with Mahatriphaladya ghrita for 84 days revealed significant improvement in the common complaints, such as feeling of dryness in the eyes (<0.001), stuck eyelids (<0.001), burning sensation (<0.001), foreign body sensation (sandy/scratchy/itching) (<0.001), rough lids/mucoid discharge/mild blepharitis (<0.001), pricking pain (<0.001), blurred vision (<0.001), inflammation/redness (<0.001), and narrowing of palpebral aperture (<0.001) faced by patients suffering from DES. Among the total 59 patients, who completed the trial, the majority were females and 50.8% of patients were belonging to Vata-Pittaja Prakriti. About 86.4% were literate and 30.5% hailed from the lower socioeconomic stratum. About 47.5% were vegetarians. The therapy also provided statistically significant changes in serum lipid profile (serum cholesterol, serum triglycerides, and low-density lipoprotein). Serum bilirubin, SGPT, SGOT, serum alkaline phosphatase, total protein, serum albumin, serum globulin, blood urea, and serum creatinine were within normal limits during the entire period and the values were compared with paired t-test before and after the trial. There was no clinical change in these parameters. No adverse drug reactions or adverse events were observed during the study (Tables 3 and 4 , Graphs 1 to 4). Among the total 62 patients who completed the trial, the majority were males and 58.1% of patients were belonging to Vata-Pittaja Prakriti. About 100% were literate and 6.5% hailed from lower socioeconomic stratum. About 48.4% were vegetarians. The therapy also provided statistically significant changes in serum lipid profile (serum cholesterol, serum triglycerides, and low-density lipoprotein). Serum bilirubin, SGPT, SGOT, serum alkaline phosphatase, total protein, serum albumin, serum globulin, blood urea, and serum creatinine were within normal limits during the entire period, and the values were compared with paired t-test after the trial. There was no detectable change in these parameters. No significant adverse drug reactions or adverse events were observed during the study (Tables 3 and 4 , Graphs 1 to 4). All the three studies were registered in the Clinical Trial Registry of India.
The data regarding demographic profile, efficacy and safety, obtained from the three studies, are given in Tables 3  and 4 , Graphs 1 to 4.
DISCUSSION
This study was to assess the safety profile of these drugs by analyzing the liver function and kidney function before and after the trial. Drug compliance and development of adverse effects, if any, were scrutinized. In-depth observations revealed that blood urea, serum uric acid, serum creatinine, total protein, serum globulin, serum albumin, SGOT, SGPT, and bilirubin levels in the body were within the range at the end of the treatment. The patients were closely monitored and no adverse events/ adverse drug reactions were reported during the trial period in the case of all three formulations and, hence, Mahatriphaladya ghrita, triphala khwath, and Anu taila can be said to be clinically safe and effective in common eye diseases.
The AC is an inclusive term that encompasses many allergic conditions that cause the symptoms of conjunctivitis, and is very common in children and adult population alike. The DES is a common disorder, which presents with dryness of eyes and gritty sensation in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain, and redness of the eyes, and photophobia. Computer vision syndrome is clinically similar to dry eye. Visual complaints include blurred vision, and ocular symptoms associated with the syndrome include sensations of burning, stinging, and photophobia. With the advent of technologies, such as the computer and mobile, improper dietetics, and lack of proper eye care, these conditions are on the rise. Ayurveda has a broad scope in this area, owing to its unique preventive and curative aspects.
In the above three studies, the prakrti of these patients was observed to be Vata Pittaja predominantly and followed by Pitta-Kaphaja prakrti. In DES, females were more affected and males were most affected in case of AC and CVS. The CVS was seen only in educated persons as it often comes with the increased use of the computer.
This study provides evidence in support of the potential safety and efficacy of three formulations that are specific to ophthalmic care: Mahatriphaladya Ghrita, 
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Triphala Kwath, and Anu Taila in subjects suffering from common eye diseases. Ghrita is Vata-Pitta Shamak and Triphala is Tridosh Shamak. Mahatriphaladya ghrita has a rejuvenating effect on eyes and is used for preventing and managing eye diseases. In these studies, significant changes were noticed in the above-mentioned qualitative parameters of AC like redness, anxiety, lacrimation, photophobia, burning sensation, and foreign body sensation, as assessed by statistical evaluation, which showed a p-value <0.001. In symptoms of DES like dryness of eye, pricking pain, mucoid discharge, stuck eyelids, blurred vision, burning sensation, and foreign body sensation, statistically significant change was observed as assessed by the statistical evaluation, which showed p-value <0.001. Also, in symptoms of CVS, like redness, headache, excessive tearing, blurred vision, dry and irritated eyes, neck and shoulder pain, double vision, photophobia, eye strain, and fatigue, statistically significant changes were observed as assessed by statistical evaluation, which showed p-value <0.001.
CONCLUSION
The study to evaluate the safety and efficacy of Mahatriphaladya ghrita, triphala kwatha, and Anu taila was conducted at two peripheral institutes of CCRAS. The analysis of outcome of these scientifically planned studies demonstrates that despite the differences in gender, socioeconomic status, age group, and Prakrti, Mahatriphaladya ghrita, triphala kwatha, and Anu taila proved to be very much safe, effective, and tolerable in the management of common eye diseases. No adverse events or adverse drug reactions pertaining to drug interaction were noticed during the trial period.
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